The New York Times reports:
The Food and Drug Administration has granted emergency authorization for the experimental antibody treatment given to President Trump shortly after he was diagnosed with Covid-19, giving doctors another option to treat Covid-19 patients as cases across the country continue to rise.
The emergency authorization for Regeneron’s drug is limited in scope: It is for people 12 and over who have tested positive for the coronavirus and who are at high risk for developing severe Covid-19.
Evidence so far suggests that antibody treatments work best early in the course of the disease, before the virus has gained a foothold in the body. Like Eli Lilly’s treatment, Regeneron’s is not authorized for use in people who are hospitalized or who need oxygen.
Read the full article.